WO2012092529A3 - Biomarqueurs protéiques de cancer du sein récurrent - Google Patents

Biomarqueurs protéiques de cancer du sein récurrent Download PDF

Info

Publication number
WO2012092529A3
WO2012092529A3 PCT/US2011/067996 US2011067996W WO2012092529A3 WO 2012092529 A3 WO2012092529 A3 WO 2012092529A3 US 2011067996 W US2011067996 W US 2011067996W WO 2012092529 A3 WO2012092529 A3 WO 2012092529A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
breast cancer
diagnostic
initial diagnosis
recurrent
Prior art date
Application number
PCT/US2011/067996
Other languages
English (en)
Other versions
WO2012092529A2 (fr
Inventor
David B. Krizman
Marlene M. Darfler
Thomas P. Conrads
Brian L. Hood
Nicholas W. BATEMAN
Original Assignee
Expression Pathology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Pathology, Inc. filed Critical Expression Pathology, Inc.
Priority to JP2013547688A priority Critical patent/JP2014502729A/ja
Priority to AU2011351990A priority patent/AU2011351990A1/en
Priority to EP11853746.3A priority patent/EP2659272A4/fr
Priority to CA2823334A priority patent/CA2823334A1/fr
Publication of WO2012092529A2 publication Critical patent/WO2012092529A2/fr
Publication of WO2012092529A3 publication Critical patent/WO2012092529A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne des protéines qui se sont révélées d'être exprimées de façon différentielle entre des cellules de cancer du sein à tumeur primaire, qui n'ont pas donné naissance à une maladie du cancer du sein récurrent après un diagnostic initial, et des cellules de cancer du sein primaire, qui ont donné naissance à une maladie du cancer du sein récurrent après un diagnostic initial. Ces protéines peuvent être utilisées soit individuellement, soit dans des combinaisons spécifiques dans des dosages protéiques de diagnostic et de pronostic sur divers échantillons biologiques provenant de patients atteints d'un cancer du sein pour indiquer la susceptibilité qu'un cancer chez des patients atteints d'un cancer du sein réapparaîtra après le diagnostic initial et le traitement. Une détermination d'une expression différentielle de ces protéines peut également être utile pour l'indication de thérapies supplémentaires pour combattre la susceptibilité d'un cancer du sein récurrent. Les protéines intactes, de longueur totale, peuvent être dosées ou des peptides issus de ces protéines peuvent être dosés en tant que rapporteurs pour ces protéines. Ces protéines peuvent également être identifiées en tant que protéines «compagnon de diagnostic », les protéines exprimées de façon différentielle, qui sont utilisées en tant qu'indicateurs de diagnostic et de pronostic, pouvant également être utilisées en tant que cibles pour une intervention thérapeutique du cancer du sein. La présente invention concerne également des versions marquées par un isotope de peptides provenant des protéines.
PCT/US2011/067996 2010-12-29 2011-12-29 Biomarqueurs protéiques de cancer du sein récurrent WO2012092529A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2013547688A JP2014502729A (ja) 2010-12-29 2011-12-29 再発性乳癌のタンパク質バイオマーカー
AU2011351990A AU2011351990A1 (en) 2010-12-29 2011-12-29 Protein biomarkers of recurrent breast cancer
EP11853746.3A EP2659272A4 (fr) 2010-12-29 2011-12-29 Biomarqueurs protéiques de cancer du sein récurrent
CA2823334A CA2823334A1 (fr) 2010-12-29 2011-12-29 Biomarqueurs proteiques de cancer du sein recurrent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428145P 2010-12-29 2010-12-29
US61/428,145 2010-12-29

Publications (2)

Publication Number Publication Date
WO2012092529A2 WO2012092529A2 (fr) 2012-07-05
WO2012092529A3 true WO2012092529A3 (fr) 2012-08-23

Family

ID=46383871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/067996 WO2012092529A2 (fr) 2010-12-29 2011-12-29 Biomarqueurs protéiques de cancer du sein récurrent

Country Status (5)

Country Link
EP (1) EP2659272A4 (fr)
JP (1) JP2014502729A (fr)
AU (1) AU2011351990A1 (fr)
CA (1) CA2823334A1 (fr)
WO (1) WO2012092529A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014526682A (ja) 2011-09-12 2014-10-06 クリエイティクス エルエルシー 標的分子を検出する非侵襲的方法
JP6646571B2 (ja) * 2013-03-13 2020-02-14 クリエイティクス エルエルシー 膵臓がんを検出するための方法および組成物
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048978A2 (fr) * 2005-10-28 2007-05-03 Biomerieux Sa Procede de detection du cancer
US20090136971A1 (en) * 2005-05-25 2009-05-28 Krizman David B Multiplex liquid tissue method for increased proteomic coverage from histopathologically processed biological samples, tissues, and cells
WO2009126969A2 (fr) * 2008-04-11 2009-10-15 Expression Pathology Inc. Biomarqueurs pour maladie endométriale
US20090263842A1 (en) * 2006-03-24 2009-10-22 Expression Pathology Method of assessing the metastatic status of a primary tumor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005029067A2 (fr) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Methode de diagnostic du cancer du sein
WO2006127861A2 (fr) * 2005-05-25 2006-11-30 Expression Pathology, Inc. Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides
CN102165075A (zh) * 2008-07-18 2011-08-24 奥洁克公司 用于检测和治疗结肠直肠癌的组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090136971A1 (en) * 2005-05-25 2009-05-28 Krizman David B Multiplex liquid tissue method for increased proteomic coverage from histopathologically processed biological samples, tissues, and cells
WO2007048978A2 (fr) * 2005-10-28 2007-05-03 Biomerieux Sa Procede de detection du cancer
US20090269744A1 (en) * 2005-10-28 2009-10-29 Exonhit Therapeutics Sa Cancer detection method
US20090263842A1 (en) * 2006-03-24 2009-10-22 Expression Pathology Method of assessing the metastatic status of a primary tumor
WO2009126969A2 (fr) * 2008-04-11 2009-10-15 Expression Pathology Inc. Biomarqueurs pour maladie endométriale

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROSS ET AL.: "Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents.", MOL CELL PROT., vol. 3, 2004, pages 1154 - 1169, XP002328690, Retrieved from the Internet <URL:http://www.mcponline.org/content/3/12/1154.long> [retrieved on 20120425] *
See also references of EP2659272A4 *

Also Published As

Publication number Publication date
CA2823334A1 (fr) 2012-07-05
EP2659272A4 (fr) 2015-07-22
JP2014502729A (ja) 2014-02-03
WO2012092529A2 (fr) 2012-07-05
EP2659272A2 (fr) 2013-11-06
AU2011351990A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
WO2009126969A3 (fr) Biomarqueurs pour maladie endométriale
WO2011028698A3 (fr) Analyses irm et optiques de protéases
WO2006081473A3 (fr) Methodes de diagnostic et de pronostic de cancers epitheliaux
WO2005044990A3 (fr) Sequences d&#39;acide nucleique differemment exprimees utilisees comme biomarqueurs du cancer
WO2005040421A3 (fr) Marqueurs de pronostic et de diagnostic des troubles de proliferation cellulaire dans les tissus mammaires
WO2007067719A3 (fr) Diagnostic de maladies humaines par détection de changements de la méthylation de l’adn
WO2007146668A3 (fr) Utilisation d&#39;imp3 en tant que marqueur pronostique de cancer
Saunders et al. Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy
WO2009019370A3 (fr) Procede de dosage de l&#39;apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2007080597A3 (fr) Nouvelles séquences de nucléotides et d&#39;acides aminés et leurs procédés d&#39;utilisation pour le diagnostic
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2011008746A3 (fr) Marqueurs dans le sérum associés à des stades précoces et à d&#39;autres stades d&#39;un cancer du sein
Santambrogio et al. External validation of a simplified BCLC staging system for early hepatocellular carcinoma
WO2012092529A3 (fr) Biomarqueurs protéiques de cancer du sein récurrent
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
WO2007020522A3 (fr) Marqueurs proteiniques permettant de diagnostiquer un cancer colorectal et utilisation de ces marqueurs comme cibles de medicament en vue du traitement de ce type de cancer
WO2016201365A3 (fr) Procédés pour le traitement de cancers
WO2017217807A3 (fr) Biomarqueur comprenant la nckap1 en tant qu&#39;ingrédient efficace pour le diagnostic du cancer colorectal ou pour la prédiction de métastases et le pronostic du cancer colorectal
EP3058067A1 (fr) Biomarqueur circulant du cancer et utilisation de celui-ci
de Almeida et al. Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma
WO2012092532A3 (fr) Biomarqueurs protéiques du cancer du sein de stade tardif
Man Tumor cell budding from focally disrupted tumor capsules: a common pathway for all breast cancer subtype derived invasion?
WO2013188823A3 (fr) Analyses pour le pronostic du cancer
Faridi et al. Expression of CCK receptors in carcinoma gallbladder and cholelithiasis: A pilot study
WO2003056341A3 (fr) Methode de diagnostic de cancers du sein, peptides associes et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11853746

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2823334

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013547688

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011351990

Country of ref document: AU

Date of ref document: 20111229

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011853746

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011853746

Country of ref document: EP